Treatment Trials

6 Clinical Trials for Various Conditions

Focus your search

      TERMINATED
      Afatinib in EGFR+NSCLC (Recurrent or Stage IV) - Patients With Poor Performance Status (ECOG 2 or 3)
      Description

      There is a medical need for improving treatment of poor performance status patients with EGFR driver mutations and documenting safety and tolerability of existing agents.

      Conditions
      Carcinoma, Non-Small-Cell LungErbB Receptors
      Talk to us
      COMPLETED
      Afatinib Treatment for Patients With EGFR Mutation Positive NSCLC Who Are Age 70 or Older
      Description

      Continuous treatment until progression or occurence of intolerable Adverse Event (AE) or end of trial. The end of trial is one year after the last patient has entered the study.

      Conditions
      Carcinoma, Non-Small-Cell LungErbB Receptors
      Talk to us
      RECRUITING
      A Phase 1/1b Study of IAM1363 in HER2 Cancers
      Description

      This is a Phase 1/1b open-label, multi-center dose escalation and dose optimization study designed to evaluate the safety and preliminary efficacy of IAM1363 in participants with advanced cancers that harbor HER2 alterations.

      Conditions
      HER2 Mutation-Related TumorsHER2HER2-positive Breast CancerHER2 + Breast CancerBrain Metastases from Solid TumorsBrain Metastases from HER2 and Breast CancerCNS MetastasesHER2-Positive Solid TumorsNSCLC (non-small Cell Lung Cancer)HER2-positive Bladder CancerHER2-positive Colorectal CancerHER2 + Gastric CancerHER2-positive Gastroesophageal Cancer
      Talk to us
      ACTIVE_NOT_RECRUITING
      Trastuzumab Deruxtecan (T-DXd) Alone or in Sequence With THP, Versus Standard Treatment (ddAC-THP), in HER2-positive Early Breast Cancer
      Description

      This study will look at the efficacy and safety of trastuzumab deruxtecan (T-DXd) in a neoadjuvant setting, in high-risk, HER2-positive early non-metastatic breast cancer.

      Conditions
      Breast NeoplasmsBreast CancerHER2-positive Early Breast Cancer
      Talk to us
      COMPLETED
      Phase 2 Trial of Selinexor (KPT-330) for Metastatic Triple Negative Breast Cancer (TNBC)
      Description

      The main purpose of this study is to see whether the combination of selinexor (KPT-330) can help people with triple negative breast cancer (TNBC). Researchers also want to study the safety and tolerability of Selinexor in TNBC patients.

      Conditions
      Breast Cancer
      Talk to us
      ACTIVE_NOT_RECRUITING
      A Study of H3B-6545 in Combination With Palbociclib in Women With Advanced or Metastatic Estrogen Receptor-Positive Human Epidermal Growth Factor Receptor-2 (HER2)-Negative Breast Cancer
      Description

      The primary objective of this study is to evaluate the safety and tolerability of H3B-6545 and palbociclib when administered in combination in order to determine the maximum tolerated dose (MTD) and/or the recommended Phase 2 dose (RP2D) of this combination in women with advanced or metastatic estrogen receptor-positive (ER+) HER2- breast cancer.

      Conditions
      Receptors, EstrogenGenes, Erbb-2Breast Neoplasms
      Talk to us